Press Releases 2026 2025 2024 2023 2022 2021 2020 2019 all September 29, 2026 Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) September 17, 2026 Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 8, 2026 Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings September 3, 2026 Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting September 2, 2026 Dyne Therapeutics to Participate in Upcoming Investor Conferences August 20, 2026 Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 29, 2026 Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights July 28, 2026 Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD) July 24, 2026 Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 23, 2026 Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares July 21, 2026 Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock July 21, 2026 Dyne Therapeutics Announces Proposed Public Offering of Common Stock July 20, 2026 Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) June 22, 2026 Dyne Therapeutics Appoints Barry Greene to Board of Directors June 18, 2026 Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 17, 2026 Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc. June 3, 2026 Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1) May 26, 2026 Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) May 20, 2026 Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 20, 2026 Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Next page › Last page » Displaying 1 - 20 of 178
